Clinical trial
Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or…
NCT00077961 · Genzyme, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00077961 |
|---|---|
| Title | Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL |
| Official title | Phase I/II Study of Rituximab Plus CAMPATH in Patients With Previously Treated Relapsed or Refractory Low-Grade Follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | CAMPATH (alemtuzumab) |
| Enrollment | 49 |
| Start date | Dec 1, 2003 |
| Primary completion | Feb 1, 2006 |
| First posted | Feb 18, 2004 |
| Last update posted | Mar 26, 2015 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: